Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1624 1625 1626 1629
This examiner grants 69% of resolved cases
Kristen Wang Romero, an examiner in Art Unit 1624 of Tech Center 1600, has managed 48 resolved cases. The allowance rate for these cases is 68.8 percent. Despite the smaller sample size of 48 resolved cases, the data provides a clear picture of the examiner's current trends and receptiveness to patent applications. The 68.8 percent allowance rate suggests that while the examiner is thorough, there is a reasonable path to grant for most applicants.
The interview lift is 31.9 percent, indicating a strong correlation between examiner interviews and successful patent grants. This suggests that verbal advocacy is a productive strategy for applicants working within this art unit to overcome objections. The 31.9 percent lift implies that the examiner is responsive to the clarifications and negotiations that occur during a live discussion. Practitioners should consider an interview as a primary tactic for advancing prosecution when a stalemate occurs in written responses.
The median days to allowance is 1158. This figure represents the typical duration of the patent prosecution process for applications that successfully reach allowance under this examiner's review. The 1158-day median serves as a critical planning tool for applicants, allowing them to forecast the timing of patent issuance and the associated costs. This timeline is particularly important in the fast-moving technology sectors often found in Tech Center 1600.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18718781 | ABL INHIBITORS AND USES THEREOF | Non-Final OA | The Regents of the University of California |
| 17932466 | 2-BETA-NAPHTHYL-ACETIC ACID ANALOGS AS AKR1C3 INHIBITORS AND METHODS OF USING SAME | Non-Final OA | VANDERBILT UNIVERSITY |
| 18263384 | SMALL MOLECULE INHIBITORS OF SALT INDUCIBLE KINASES | Non-Final OA | The General Hospital Corporation |
| 18399675 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER | Non-Final OA | INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY |
| 18605320 | Compositions of Azadirachta Indica and Methods of Treating Cancer | Non-Final OA | Board of Regents, The University of Texas System |
| 18728949 | ISOCITRATE DEHYDROGENASE 1 INHIBITORS AND METHODS OF USE THEREOF | Non-Final OA | CASE WESTERN RESERVE UNIVERSITY |
| 18768262 | COMPOUNDS FOR THE TREATMENT OF GLYCOGEN STORAGE DISORDERS | Non-Final OA | RAMOT AT TEL-AVIV UNIVERSITY LTD. |
| 18549638 | TRICYCLIC PYRIMIDINES AS CYCLIN-DEPENDENT KINASE 7 (CDK7) INHIBITORS | Non-Final OA | JANSSEN PHARMACEUTICA NV |
| 18257541 | FUSED PYRIMIDINE COMPOUNDS AS INHIBITORS OF MENIN-MLL INTERACTION | Final Rejection | Biomea Fusion, Inc. |
| 18263318 | CRYSTALLINE FORM OF A PIPERAZINYL-THIAZOLE DERIVATIVE | Non-Final OA | Idorsia Pharmaceuticals Ltd |
| 18864708 | METHODS OF TREATING ULK3-ASSOCIATED CANCERS | Non-Final OA | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. |
| 18682879 | SMALL MOLECULE UREA DERIVATIVES AS STING ANTAGONISTS | Non-Final OA | CURADEV PHARMA PVT. LTD. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy